More News

Circio enters in vivo cell therapy evaluation agreement with Acuitas Therapeutics

Jim Cornall -
Circio Holding ASA has initiated a technology evaluation agreement in the area of in vivo CAR-T cell therapy with...

CRISPR variant selectively targets tumour DNA

Jim Cornall -
Cancer cells excel at evading detection, but subtle chemical differences set them apart from healthy cells. Wageningen University &...

AI-powered biochip detects genetic markers in 20 minutes

Jim Cornall -
A team of scientists from Nanyang Technological University, Singapore (NTU Singapore) has developed a new biochip that, when paired...

Base to Base biotech podcast 55: Beating transplant challenges and a circular supply chain

Jim Cornall -
This week, our conversations are with Steve Perrin, president and CSO of Eledon Pharmaceuticals, and Jason Bock, CEO and...

Fortitude Biomedicines announces axial spondyloarthritis lead programme

Jim Cornall -
Fortitude Biomedicines, Inc. has announced that its lead programme is a first-in-class T-cell targeting bispecific antibody for the potential...

New study shows increasing value of real-world data in clinical trials

Jim Cornall -
New research by Tufts Center for the Study of Drug Development (CSDD) documents the growing importance of real-world data...

Delivering healthy mitochondria to diseased cells

Jim Cornall -
Scientists led by Botond Roska at the Institute of Molecular and Clinical Ophthalmology Basel (IOB) have developed MitoCatch, a...

Breakthrough data show complete tumour eradication and durable protection in aggressive brain cancer model

Jim Cornall -
Trogenix Ltd has announced the publication of its breakthrough pre-clinical data in Nature reporting complete tumour eradication and durable...

New formulation of SCD1 inhibitor can reach brain

Jim Cornall -
Galmed Pharmaceuticals Ltd. has announced the breakthrough development of a brain penetrating new formulation of Aramchol. Crossing of the...

Supporting biotech innovation in Singapore

Jim Cornall -
NSG Bio has signed a memorandum of understanding (MoU) with Charles River Laboratories aimed at strengthening support for biotech...

SonoNeu exits stealth to advance sonogenetics into clinic

Jim Cornall -
SonoNeu, a spin-out from the Salk Institute and co-founded by General Inception, has emerged from stealth as part of...

GATC Health and UC Irvine publication validates AI-platform for opioid use disorder treatment

Jim Cornall -
GATC Health Corp and researchers from the University of California, Irvine (UCI) have published a joint study in the...

Gilead to acquire Tubulis

Jim Cornall -
Gilead Sciences, Inc. has entered into a definitive agreement to acquire Tubulis GmbH, a private clinical-stage biotechnology company developing...

Fast Track Designation for T-cell therapy enhanced with membrane-tethered IL-12 booster

Jim Cornall -
A2 Biotherapeutics, Inc. (A2 Bio) has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track...

Walks to support Lennox-Gastaut syndrome research

Jim Cornall -
The Lennox-Gastaut Syndrome (LGS) Foundation is mobilising Walks for LGS Research around the US this month. The event unites...

Precision nanomedicine to target most challenging tumours

Jim Cornall -
Eascra Biotech is leveraging the International Space Station (ISS) National Laboratory to advance the next generation of targeted cancer...

Base to Base biotech podcast 54: Parkinson’s disease and peptides

Jim Cornall -
This week, because April 11 is World Parkinson’s Day, we chat with Dieter Willbold, CSO of Priavoid, and Antje...

Study shows prostate cancer can be detected through urine-based liquid biopsy

Jim Cornall -
PanGIA Biotech, Inc. has announced a peer-reviewed clinical study published in Diagnostics, "Urine-Based Machine Learning Assay Detects Prostate Cancer,"...

Cyclerion and Korsana announce merger

Jim Cornall -
Cyclerion Therapeutics, Inc. and Korsana Biosciences, Inc. have entered into a definitive merger agreement for an all-stock transaction. Upon...

“Groundbreaking” data for Charcot-Marie-Tooth disease type 1A treatment

Jim Cornall -
Armatus Bio has announced the publication of foundational data in Molecular Therapy Nucleic Acids describing the safety and biodistribution...

Positive results from moderate-to-severe atopic dermatitis trial

Jim Cornall -
Enveda has announced positive phase 1b results for ENV-294, a first-in-class, oral, once-daily investigational therapy, in patients with moderate-to-severe...